Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in its own shares conducted on July 8, 2025, and filed on July 9, 2025. The filing details a share repurchase executed through Merrill Lynch International as part of an existing buyback programme established via a non-discretionary agreement on June 4, 2025.
Key Financial Metrics
The filing focuses exclusively on capital allocation activities regarding share repurchases. No revenue, profit, cash flow, or debt metrics are provided in this specific document.
- Shares Purchased (July 8, 2025): 480,940 ordinary shares.
- Price Range (GBp): Lowest 1,388.50p; Highest 1,416.50p.
- Volume-Weighted Average Price (GBp): 1,405.17p.
- Trading Venue: London Stock Exchange (XLON).
- Cumulative Buyback (Since June 4, 2025): 10,944,632 ordinary shares.
- Treasury Shares Held: 229,079,015 ordinary shares.
- Shares in Issue (Excluding Treasury): 4,086,302,835 ordinary shares.
- Treasury Voting Rights Percentage: 5.61%.
Material Changes
There are no material changes to financial performance reported in this filing. The primary change is the reduction of shares in issue and the increase in treasury shares following the July 8 transaction. The total number of voting rights remains 4,086,302,835, which serves as the denominator for shareholder notification thresholds under FCA Disclosure Guidance and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in GSK's 2024 Annual Report on Form 20-F and Q1 2025 Results. The repurchase was executed pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on June 4, 2025.
- Confirm the impact of the 5.61% treasury holding on earnings per share (EPS) calculations.
- Review the "Risk Factors" section of the 2024 Form 20-F for context on the forward-looking statement disclaimer.
- Check subsequent filings to monitor the pace of the non-discretionary buyback agreement.